Particulate delivery systems for vaccines: what can we expect?
about
Nanoparticulate adjuvants and delivery systems for allergen immunotherapyCurrent Status of Veterinary VaccinesMucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motilityEffect of Experimental Parameters on Alginate/Chitosan Microparticles for BCG Encapsulation.Engineering mycobacteria for the production of self-assembling biopolyesters displaying mycobacterial antigens for use as tuberculosis vaccine.Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses.Multifunctional dendritic cell-targeting polymeric microparticles: engineering new vaccines for type 1 diabetes.Liposome-based delivery system for vaccine candidates: constructing an effective formulation.Bile salts-containing vesicles: promising pharmaceutical carriers for oral delivery of poorly water-soluble drugs and peptide/protein-based therapeutics or vaccines.Duality of β-glucan microparticles: antigen carrier and immunostimulants.Novel vaccine delivery system induces robust humoral and cellular immune responses based on multiple mechanisms.Improved Antitumor Activity of a Therapeutic Melanoma Vaccine through the Use of the Dual COX-2/5-LO Inhibitor LicofeloneSpray-dried chitosan microparticles for cellular delivery of an antigenic protein: physico-chemical properties and cellular uptake by dendritic cells and macrophages.Exploiting bilosomes for delivering bioactive polysaccharide isolated from Enteromorpha intestinalis for hacking hepatocellular carcinoma.Development and characterization of LTA-appended chitosan nanoparticles for mucosal immunization against hepatitis B.Particulate transepithelial drug carriers: barriers and functional polymers
P2860
Q26825418-A13390B4-8AF0-4209-B5B9-D414D4B39558Q27480923-BE16BE3E-9935-4DC1-8E10-13CB85BA466FQ30496874-C8CF8DF8-9B95-4DE7-B234-97EE99C7F7D8Q36941463-10104927-6729-4C68-8229-7B6AD24B4FADQ37644063-52CB17F5-B5C5-412C-B413-D88B3BD3CCC8Q37785952-D2B238B8-1E1E-4CB3-A143-C35D76887FE8Q37820820-F2556B2C-0277-4445-AABE-1413F3A707E3Q38068245-9A5284B6-5B70-4C73-8DB4-8892288A02F8Q38267521-32109774-2FD5-4467-B928-F70FAD296A7EQ40688473-0A351242-CD0F-4232-92DF-FD260E25A44DQ42235032-517D09DA-F428-4CF9-B4A7-482346FD00CEQ42358876-D2104754-4367-43B7-A835-C2E80C9DA290Q46930554-AF1E54C8-D84C-4911-A4C4-E76B443E386DQ47426135-57A9A99C-01B1-43E0-B3C8-E0B24F8C9A7EQ50866760-67D779F5-A78B-4BEE-9345-7246ABD018B8Q58385253-E5F25C8A-DAD1-42FD-814F-1DC1243C9466
P2860
Particulate delivery systems for vaccines: what can we expect?
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Particulate delivery systems for vaccines: what can we expect?
@ast
Particulate delivery systems for vaccines: what can we expect?
@en
type
label
Particulate delivery systems for vaccines: what can we expect?
@ast
Particulate delivery systems for vaccines: what can we expect?
@en
prefLabel
Particulate delivery systems for vaccines: what can we expect?
@ast
Particulate delivery systems for vaccines: what can we expect?
@en
P2860
P356
P1476
Particulate delivery systems for vaccines: what can we expect?
@en
P2093
Vincent W Bramwell
Yvonne Perrie
P2860
P304
P356
10.1211/JPP.58.6.0002
P577
2006-06-01T00:00:00Z